Protego Biopharma
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $130.0Mattributed |
|---|---|
| Latest round | series-d+, $130.0M, 2025-12-01attributed |
| Founded | 2020 |
| Headquarters | USA |
| Industry | bio |
| Stage | series-b+ |
| Website | protegobio.com |
Protego Biopharma develops small-molecule pharmacological chaperones that restore proper protein folding to treat protein misfolding diseases. It targets patients with conditions including cardiomyopathy and AL amyloidosis. The company was built on the success of tafamidis, an FDA-approved amyloidosis treatment discovered by its cofounders.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-d+ | $130.0M | undisclosed |
Detected tech stack
Apache HTTP Server, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $130.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $130.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | protegobio.com, read 2026-05-07 |
| Description | self-reported | protegobio.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.